Physician profile
Simon Maltais
NPI 1457665911
$20,338.56
in general payments reported to CMS, 2019-2025
20 companies · $2,411 in 2025
The $2,411 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.81 · 2020: $64.91 · 2021: $361 · 2022: $1,515 · 2023: $8,908 · 2024: $6,997 · 2025: $2,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $4,955 · Travel and Lodging: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,893.75 |
| Food and Beverage | $4,955.10 |
| Travel and Lodging | $2,467.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $12,727.59 | 2020-2024 | Konect Resilia, Inspiris Resilia Aortic Valve |
| Abiomed | $2,237.96 | 2022-2025 | Impella |
| Kls-Martin L.P. | $1,721.03 | 2022-2025 | |
| Artivion, INC. | $1,106.26 | 2022-2024 | Cryovalve Sg Pulmonary Human Heart Valve, Cardiac Non-Synergraft |
| Orthofix Medical, INC. | $779.20 | 2024 | Meridian |
| Abbott Laboratories | $607.58 | 2019-2025 | Mitraclip, Perclose Prostyle, Diamondback Coronary |
| Lemaitre Vascular, INC. | $494.10 | 2023-2025 | Restoreflow, Artegraft Vascular Graft |
| W. L. Gore & Associates, INC. | $146.40 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Shockwave Medical, INC | $133.82 | 2025 | |
| Medtronic, INC. | $110.90 | 2021 | |
| Baxter Healthcare | $77.90 | 2025 | Perclot |
| Otsuka America Pharmaceutical, INC. | $35.89 | 2022 | |
| Amgen INC. | $30.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.38 | 2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $23.15 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.37 | 2021 | |
| Angiodynamics, INC. | $15.65 | 2024 | Angiovac |
| Pfizer INC. | $15.56 | 2024 | |
| Haemonetics Corporation | $15.04 | 2023 | Teg6s Hemostasis System |
| Philips North America LLC | $14.81 | 2025 | IV Other |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Maltais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.